Grand Flight Investment
VC Fund
Shanghai, China
Grand Flight Investment is a VC fund in Shanghai focused on Health Care and Internet. Grand Flight Investment engages in expansion stage growth investment of different industries such as automotive, education, medical, corporate services, new energy and environmental protection.It was established in mid-2016. With Far East Horizon (HK.03360) as its main initiator, this alternative investment platform was jointly established bywell-known domestic and international financial holding companies, insurance companies and FOF
- Total investments:
- 52
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Grand Flight Investment invests in
Stages Grand Flight Investment invests in
Countries Grand Flight Investment invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jun Yang
|
|||
Linliang Hao
|
|||
Wei Wang
|
|||
2 more contacts available
Investment Focus
Industry
- Health Care 8 (15%)
- Internet 6 (12%)
- Biotechnology 6 (12%)
- Medical 5 (10%)
- Automotive 5 (10%)
Stage
- Series B 15 (29%)
- Series C 11 (21%)
- Series A 8 (15%)
- Series D 3 (6%)
- Venture - Series Unknown 3 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jun Yang
Managing Director
|
Managing Director | Total investments: 5 | Find email | |
|
Linliang Hao
CFO
|
CFO | Total investments: 0 | Find email | |
|
Wei Wang
Director of Compliance
|
Director of Compliance | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
YolTech Therapeutics
|
Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $73.8M / Series C / May 29, 2026 | |
Kingkong.tech
|
Kingkong.tech is a Chinese company specializing in the research and development of magnetic encoders, particularly for robotics applications. Their product lineup includes high-resolution encoders such as the MBS, MPT, and DPT series, offering resolutions up to 24 bits and angular accuracies as precise. | $14.5M / Series A / Mar 23, 2026 | |
Aurora Starcom
|
Aurora Starcom is a national high-tech company specialising in the research and development of space laser communication technology. | $43.2M / Series A / Feb 06, 2026 | |
|
YolTech Therapeutics
|
Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $42.1M / Series B / Sep 11, 2025 | |
Tejin Intelligence
|
Tejin Intelligence is deeply involved in radio sensing and spectrum big data analysis technology, and is dedicated to providing the world's leading low-altitude safety management and control solutions, assisting in the development of new ground-air integrated three-dimensional security infrastructure for smart cities, and striving for refinedmanagement of urban low-altitude airspace. | $13.8M / Series B / May 20, 2024 | |
Sino-Biocan
|
Zhongbo Ruikang focuses on the research and development of domestic tools in the field of cell and gene therapy, mainly to assist customers in realizing the "continuous, closed, disposable, consistent, scalable, automated, modular, and medical deviceization of cell preparation industrialization. | $13.9M / Series B / Mar 04, 2024 | |
Hope Medicine
|
Hope Medicine is committed to researching, developing and commercializing the first innovative drugs aimed at improving the quality of life for a wide range of popular male and female diseases. | $28.1M / Series B / Feb 07, 2024 | |
DIAGENS
|
DIAGENS is a Hangzhou-based biotechnology firm, providing in-vitro diagnostic (IVD) products and other medical equipment. | $14.5M / Series C / Apr 12, 2023 | |
Timely technology
|
Shide Technology is a spacecraft manufacturer dedicated to the research and development of manned electric aircraft. | $14.2M / Seed / Feb 08, 2023 | |
TCab Tech
|
TCab Tech is building a air mobility ecosystem in order to provide the general public with zero-emission airborne ridesharing. | $14.7M / Seed / Feb 08, 2023 | |
| See all 52 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Grand Flight Investment invest in?
Grand Flight Investment invests primarily in Health Care, Internet and Biotechnology startups, most often at Series B and Series C stage. Most of the 52 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Grand Flight Investment?
Public channels for Grand Flight Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Grand Flight Investment?
The team at Grand Flight Investment includes Jun Yang (Managing Director), Linliang Hao (CFO) and Wei Wang (Director of Compliance). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
